Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study to Re-assess and Re-confirm Data Previously Recorded About the Incidence and Severity of Acute Abdominal "Pancreatitis" Episodes in Lipoprotein Lipase Deficient (LPLD) Subjects Previously Enrolled on AMT Clinical Studies

This study is enrolling participants by invitation only.
Sponsor:
Collaborator:
The Clinical Trial Company
Information provided by (Responsible Party):
Amsterdam Molecular Therapeutics
ClinicalTrials.gov Identifier:
NCT01448577
First received: October 3, 2011
Last updated: October 6, 2011
Last verified: October 2011
  Purpose

Lipoprotein lipase deficiency (LPLD) is an autosomal recessive inherited condition caused by homozygosity or compound heterozygosity for mutations within the LPL gene. LPLD results in subjects presenting with fasting plasma triglyceride (TG) levels of > 10 mmol/l. LPLD typically presents in infancy or childhood with usual complaints of severe abdominal pain, repetitive colicky pains and repeated episodes of acute pancreatitis The most severe clinical complication associated with LPLD is acute pancreatitis. Pancreatitis in an LPLD subject often leads to prolonged hospital admissions (sometimes up to weeks). Subjects who survive repeated episodes of acute pancreatitis may develop chronic pancreatitis, ultimately resulting in endocrine and exocrine pancreatic insufficiency.

The clinical manifestations of acute pancreatitis episodes related to LPLD are largely indistinguishable from acute pancreatitis due to other causes. However, collection of data relating to hospital admissions, laboratory test results, scan images and adverse events occurring concomitantly to the acute pancreatic episode should allow elimination of other causes of pancreatitis (e.g gallstones etc) and ultimately allow confirmation of LPLD-related acute pancreatitis. Characterization of the presentation of symptoms which occur around the time of known episodes of LPLD-related acute pancreatitis should also permit identification of episodes of acute pancreatitis which have previously been considered as unrelated or even unrecognized.

The objective of the study is to re-assess and re-confirm data previously recorded about the incidence and severity of acute abdominal "pancreatitis" episodes in LPLD subjects previously enrolled on AMT clinical studies. To assess and document the presentation of acute abdominal episodes that occur around known episodes of pancreatitis and to permit the identification of possible new previously unrecorded episodes of pancreatitis based upon predefined diagnostic criteria. The objective is to recruit the 27 subjects previously enrolled in the above mentioned clinical studies.


Condition
Lipoprotein Lipase Deficiency

Study Type: Observational
Study Design: Observational Model: Cohort
Official Title: A Clinical Records Review Study of the Frequency and Severity of Acute Abdominal "Pancreatitis" Episodes Reported From LPLD Subjects Previously Recruited to Clinical Studies PREPARATION-02, CT-AMT-011-01 and CT-AMT-011-02

Resource links provided by NLM:


Further study details as provided by Amsterdam Molecular Therapeutics:

Primary Outcome Measures:
  • Incidence and severity of acute abdominal "pancreatitis" episodes in LPLD subjects [ Time Frame: Retrospective ] [ Designated as safety issue: No ]
    To re-assess and re-confirm data previously recorded about the incidence and severity of acute abdominal "pancreatitis" episodes in LPLD subjects previously enrolled on clinical studies PREPARATION-02, CT-AMT-011-02 and CT-AMT-011-02. Acute abdominal episodes will be reviewed and adjudicated using the Atlanta diagnostic criteria for acute pancreatitis


Secondary Outcome Measures:
  • Acute abdominal episodes that occur around known episodes of LPLD pancreatitis [ Time Frame: Retrospective ] [ Designated as safety issue: No ]
    To assess and document the presentation of acute abdominal episodes that occur around known episodes of LPLD pancreatitis

  • Previously unrecorded episodes of pancreatitis [ Time Frame: Retrospective ] [ Designated as safety issue: No ]

    To permit identification as far as possible new previously unrecorded episodes of pancreatitis based upon the Atlanta diagnostic criteria for acute pancreatitis

    • Recorded in LPLD subjects past medical history prior to alipogene tiparvovec therapy, and
    • Recorded in LPLD subjects, post alipogene tiparvovec therapy

  • Initial onset, duration, and frequency of pancreatitis episodes [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]
    To document initial onset, duration, and frequency of pancreatitis episodes in the defined LPLD subject population over a period of five years

  • Initial onset and presence of chronic pancreatitis [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]
    To assess the initial onset and presence of chronic pancreatitis over a period of five years

  • initial onset and presence of the late complications of chronic pancreatitis [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]
    To determine the initial onset and presence of the late complications of chronic pancreatitis including exocrine and endocrine insufficiency over a period of five years


Enrollment: 22
Study Start Date: November 2010
Estimated Study Completion Date: March 2016
Estimated Primary Completion Date: March 2016 (Final data collection date for primary outcome measure)
Groups/Cohorts
Dose 3 x 1011 gc/kg
Subjects received AMT-011 at dose 3 x 1011 gc/kg
Dose 1 x 1012 gc/kg
Subjects received AMT-011 at dose 1 x 1012 gc/kg

Detailed Description:

Lipoprotein lipase deficiency (LPLD) is an autosomal recessive inherited condition caused by homozygosity or compound heterozygosity for mutations within the LPL gene.

The most severe clinical complication associated with LPLD is acute pancreatitis. Pancreatitis in an LPLD subject often leads to prolonged hospital admissions. Subjects who survive repeated episodes of acute pancreatitis may develop chronic pancreatitis, ultimately resulting in endocrine and exocrine pancreatic insufficiency.

The clinical manifestations of acute pancreatitis episodes related to LPLD are largely indistinguishable from acute pancreatitis due to other causes. However, collection of data relating to hospital admissions, laboratory test results, scan images and adverse events occurring concomitantly to the acute pancreatic episode should allow elimination of other causes of pancreatitis (e.g. gallstones etc) and ultimately allow confirmation of LPLD-related acute pancreatitis. Characterisation of the presentation of symptoms which occur around the time of known episodes of LPLD-related acute pancreatitis should also permit identification of episodes of acute pancreatitis which have previously been considered as unrelated or even unrecognized.

Alipogene tiparvovec (Glybera®) is in development for the therapy of LPLD. In summary, alipogene tiparvovec contains the human lipoprotein (LPL) gene variant LPLS447X in a non-replicating vector in solution administered in a one-time series of intramuscular injections in the arms/legs.

Studies conducted to date with Glybera have evaluated total triglyceride levels as a surrogate marker for efficacy and have not evaluated a clinical endpoint such as acute pancreatitis episodes as a primary endpoint. Post-hoc analysis has suggested that there may be a reduction in the frequency of acute abdominal pancreatitis episodes reported following treatment compared to the frequency reported pre-treatment from past medical history records. The recorded episodes used in this post-hoc analysis were collected from medical history and adverse event data but no uniform criteria were used to classify these as episodes of acute pancreatitis. Review of the post hoc analysis has raised questions that the recorded past medical history of pancreatitis episodes may be inaccurate with respect to diagnosis and number of episodes.

In this case record review study, data will be collected on pancreatitis episodes from subjects who previously enrolled in studies PREPARATION-02 (observational), CT-AMT-011-01 and CT-AMT-011-02. In studies CT-AMT-011-01 and CT-AMT-011-02 subjects received AMT-011 at either dose 3 x 1011 gc/kg or 1 x 1012 gc/kg. Data obtained from medical records, hospital admission/discharge charts, laboratory results and imaging scans will be evaluated for evidence of LPLD-related episodes of pancreatitis by an expert review panel. The evaluation will consider data collected from three time periods:

  • subjects entire past medical history,
  • the period after enrolment into study but prior to AMT-011 therapy,
  • the period post-administration of AMT-011.

Data from the subjects who did not progress to receive AMT-011 will be evaluated as a control group using data collected from past medical history and from the period after enrolment in the PREPARATION-02.

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Subjects who previously enrolled in studies PREPARATION-02 (observational), CT-AMT-011-01 and CT-AMT-011-02

Criteria

Inclusion Criteria:

  • Subjects must have participated in clinical studies study PREPARATION-02, CT-AMT-011-01 or CT-AMT-011-02,
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01448577

Locations
Canada, Quebec
ECOGENE-21 Clinical Trial Center
Chicoutimi, Quebec, Canada, G7H 7P2
Canada
La Clinique de Maladies Lipidiques de Quebec Inc. (CMLQ, Inc.)
Quebec, Canada, G1V 4M6
Sponsors and Collaborators
Amsterdam Molecular Therapeutics
The Clinical Trial Company
Investigators
Principal Investigator: Daniel Gaudet, MD, PhD Ecogene-21 Clinical Trial Center Chicoutimi
  More Information

Additional Information:
Publications:
Responsible Party: Amsterdam Molecular Therapeutics
ClinicalTrials.gov Identifier: NCT01448577     History of Changes
Other Study ID Numbers: CT-AMT-011-03
Study First Received: October 3, 2011
Last Updated: October 6, 2011
Health Authority: Canada: Health Canada

Additional relevant MeSH terms:
Hyperlipoproteinemia Type I
Pancreatitis
Digestive System Diseases
Dyslipidemias
Genetic Diseases, Inborn
Hyperlipidemias
Hyperlipoproteinemias
Lipid Metabolism Disorders
Lipid Metabolism, Inborn Errors
Metabolic Diseases
Metabolism, Inborn Errors
Pancreatic Diseases

ClinicalTrials.gov processed this record on November 27, 2014